Add-on Acquisition • Life Science

AREVA Med Acquires Macrocyclics

On October 20, 2011, AREVA Med acquired life science company Macrocyclics

Acquisition Context

This is AREVA Med’s 1st transaction in the Life Science sector.
This is AREVA Med’s 1st transaction in the United States.
This is AREVA Med’s 1st transaction in Texas.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	October 20, 2011
Target	Macrocyclics
Sector	Life Science
Buyer(s)	AREVA Med
Deal Type	Add-on Acquisition

Target Company

Macrocyclics

Dallas, Texas, United States

Macrocyclics, Inc. is a provider of chelators*, chemical agents that allow for the attachment of antibodies or proteins with radioactive isotopes for the development of powerful nuclear medical treatments targeted against aggressive types of cancer.

Explore More Deals

Browse All 215,130 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

AREVA Med

Bethesda, Maryland, United States

Category	Company
Founded	2009
Sector	Life Science

DESCRIPTION

AREVA Med LLC is a developer of innovative methods for producing lead-212 (212Pb), a rare radioactive isotope at the heart of promising research projects in nuclear medicine to develop new treatments against cancer.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
State: Texas	1 of 1
Country: United States	1 of 1
Year: 2011	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - Texas M&A - United States M&A - 2011 M&A